Key points are not available for this paper at this time.
A loss-of-function variant in HSD17B13 was associated with a reduced risk of chronic liver disease and of progression from steatosis to steatohepatitis. (Funded by Regeneron Pharmaceuticals and others.).
Abul‐Husn et al. (Wed,) studied this question.